Another GWAS approach, using 491 DLBCL WGS data (31% discovery cohort; 69% validation cohort) and 1000 control WGS data, found NF-κB pathway activation by 3′ cis-regulatory mutations on NFKBIZ but only on ABC DLBCL subtype which was later correlated with increasing expression on different DLBCL cell lines when compared to the non-mutated ones. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.